Acute lymphoblastic leukaemia is a most common cancer seen in children. Credit: National Research Council Canada.

The Human Health Therapeutics (HHT) Research Centre of the National Research Council of Canada (NRC) has received a $1.66m grant to carry out research on paediatric acute lymphoblastic leukaemia (ALL).

The Canadian Cancer Society announced the grant at an event in Montréal. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The research project will be carried out by the centre in partnership with Sainte-Justine Mother and Child University Hospital Centre (SJUHC) and Jenthera Therapeutics.

Led by HHT research officer Dr Richard Marcotte, the research intends to create a new therapy product to enhance treatment outcomes in children with ALL.

This project is part of SJUHC and NRC’s collaboration centre named NRC-CHU Sainte-Justine Collaborative Unit for Translational Research. 

See Also:

The goal of this centre is to combine the capabilities and technologies to expedite the translation of discoveries to the patient by enhancing diagnostics, discovering new therapies and updating clinical analytics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dr Marcotte said: “This funding represents a great opportunity to translate some of our basic scientific findings to the clinic, with the hope that it will ultimately help treat children diagnosed with this terrible disease.”

The most common cancer detected in children, ALL represents approximately 85% of all childhood leukaemia cases. 

The new therapy is expected to help treat 10% to 15% of patients who fail to respond or relapse after they receive initial treatment.

It could improve the prognosis for these leukaemia patients.

While the therapy approaches available currently for ALL are comparatively effective, the chemotherapeutic drugs have serious side effects. 

Long-term therapy-linked conditions can be seen in children who survive ALL.